Division of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Front Endocrinol (Lausanne). 2022 Jun 20;13:917773. doi: 10.3389/fendo.2022.917773. eCollection 2022.
The incidence and prevalence of chronic kidney disease (CKD) continue to increase worldwide remaining as a major public health burden. CKD eventually progresses to end-stage kidney failure and patients with CKD have high morbidity and mortality. Sirtuin 1 (SIRT1), a NAD+-dependent deacetylases, has significant renal protective effects through its regulation of fibrosis, apoptosis, and senescence, oxidative stress, inflammation and aging process. The renal protective effects of Sirt1 have been described in many kidney diseases such as diabetic kidney disease and HIV-related kidney disease. SIRT1 also has protective effects against vascular calcification and therefore could be developed as a therapy for both CKD and CKD complications. In this narrative review, we will give an overview of the recent progress on the role of SIRT1 and its downstream pathways in CKD. We will also discuss potential therapeutic approach by activating SIRT1-related pathway in patients with CKD. The purpose is to hope to provide some insights on the future direction of the research in the field of SIRT1 for CKD.
慢性肾脏病（CKD）的发病率和患病率在全球范围内持续上升，仍然是一个主要的公共卫生负担。CKD 最终会进展为终末期肾衰竭，CKD 患者的发病率和死亡率很高。Sirtuin 1（SIRT1）是一种 NAD+-依赖性去乙酰化酶，通过调节纤维化、细胞凋亡和衰老、氧化应激、炎症和衰老过程，具有显著的肾脏保护作用。Sirt1 在许多肾脏疾病中都具有肾脏保护作用，如糖尿病肾病和 HIV 相关肾病。SIRT1 对血管钙化也有保护作用，因此可以开发用于治疗 CKD 和 CKD 并发症的药物。在这篇综述中，我们将概述 SIRT1 及其下游途径在 CKD 中的作用的最新进展。我们还将讨论通过激活 CKD 患者的 SIRT1 相关途径的潜在治疗方法。目的是希望为 SIRT1 治疗 CKD 领域的研究提供一些未来的研究方向。
